Home › Cancro alla prostata › Illinois
Studi clinici su Cancro alla prostata nello stato di Illinois
64 studi su Cancro alla prostata cercano partecipanti presso sedi nello stato di Illinois.
Città nello stato di Illinois
- Chicago45 studi
- Cicero14 studi
- Decatur12 studi
- Naperville10 studi
- Peoria9 studi
- Aurora9 studi
- Evanston9 studi
- Champaign8 studi
- Bloomington7 studi
- Danville7 studi
- Charleston7 studi
- Waukegan6 studi
- Galesburg6 studi
- North Peoria6 studi
- Springfield6 studi
- Joliet5 studi
- Arlington Heights3 studi
- Carbondale3 studi
Testo ufficiale dello studio (inglese)
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- Illinois CancerCare-Carthage, Carthage
- e altri 31
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 2 ott 2026 · NCT06931340Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
- Northwestern University, Chicago
- Cancer Care Specialists of Illinois - Decatur, Decatur
- Decatur Memorial Hospital, Decatur
- e altri 8
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 2 ott 2026 · NCT07200830A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Chicago Hospital, Chicago
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06465069Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- Advocate Outpatient Center - Aurora, Aurora
- e altri 54
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- Carle at The Riverfront, Danville
- e altri 11
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06632977A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- University of Illinois Cancer Center, Chicago
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06172478Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Rush MD Anderson Cancer Center, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- Carle at The Riverfront, Danville
- e altri 12
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT03866382Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- Northwestern Medicine Chicago Proton Center, Warrenville
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 29 set 2026 · NCT01492972Precision-Based Genomics in Prostate Cancer
- NorthShore University HealthSystem, Evanston
In reclutamentoStudio osservazionale
Età da 18 a 120 · Uomini · Aggiornato il 28 set 2026 · NCT04706663DESTINY-PANTUMOUR04
- Research Site, Decatur
In reclutamentoStudio osservazionale
Età da 18 a 130 · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07124000A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Illinois Cancer Care ( Site 0104), Peoria
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06136650This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- Associated Urological Specialists - Chicago Ridge, Chicago Ridge
- Cancer Care Specialists of Illinois, Decatur
- Cancer Care Specialists of Illinois, O'Fallon
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 24 set 2026 · NCT07028853Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
- University of Chicago, Chicago
In reclutamentoFase 2/3
Età da 18 a 100 · Uomini · Aggiornato il 22 set 2026 · NCT06780670A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- University of Illinois Chicago, Chicago
- Cancer Care Specialists of Illinois, Decatur
- Midwestern Regional Medical Center dba City of Hope Chicago, Zion
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 22 set 2026 · NCT07213674Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- Northwestern University, Chicago
- University of Illinois Cancer Center at Chicago, Chicago
In reclutamentoFase 3
Età da 18 a 100 · Uomini · Aggiornato il 22 set 2026 · NCT06855277A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Research Site, Chicago
- Research Site, Chicago Ridge
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 18 set 2026 · NCT06952803A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Rush University Medical Center-Hematology and Oncology ( Site 0028), Chicago
- University of Illinois at Chicago-University of Illinois Cancer Center ( Site 0063), Chicago
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 17 set 2026 · NCT06925737Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- NorthShore University Health System, Glenbrook Hospital, Glenview
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 11 set 2026 · NCT06056830Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- Alton Memorial Hospital, Alton
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- e altri 39
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 10 set 2026 · NCT05946213A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
- University of Illinois Hospital & Health Sciences System, Chicago
In reclutamentoFase 1
Età 18 e oltre · Uomini · Aggiornato il 8 set 2026 · NCT05800665A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
- Associated Urological Specialists, Chicago Ridge
- NorthShore University HealthSystem, Evanston
In reclutamentoFase 2
Età 18 e oltre · Uomini · Aggiornato il 3 set 2026 · NCT07005154MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
In reclutamento
Età 18 e oltre · Uomini · Aggiornato il 1 set 2026 · NCT05710380A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
- University of Chicago Comprehensive Cancer Center, Chicago
- Endeavor Health, Evanston
In reclutamentoFase 2
Età 18 e oltre · Uomini · Aggiornato il 31 ago 2026 · NCT05726292AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Research Site, O'Fallon
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 26 ago 2026 · NCT07611110A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
- Jesse Brown VA Medical Center, Chicago, IL, Chicago
In reclutamentoFase 2
Età 18 e oltre · Uomini · Aggiornato il 25 ago 2026 · NCT05593497A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
- University of Chicago, Chicago
In reclutamentoFase 1/2
Età 18 e oltre · Uomini · Aggiornato il 20 ago 2026 · NCT06785636Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Alton Memorial Hospital, Alton
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- e altri 42
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 19 ago 2026 · NCT04423211Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- University of Chicago Medical Center, Chicago
In reclutamentoFase 1
Età da 18 a 100 · Uomini · Aggiornato il 13 ago 2026 · NCT05519449Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Chicago
In reclutamentoFase 1/2
Età da 18 a 130 · Tutti i sessi · Aggiornato il 12 ago 2026 · NCT05417594PSMA PET Combined With MRI for the Detection of PCa
- UroPartners,LLC, Chicago
In reclutamentoFase 3Volontari sani benvenuti
Età 18 e oltre · Uomini · Aggiornato il 23 lug 2026 · NCT07052214PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
- Rush MD Anderson, Chicago
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 22 lug 2026 · NCT06274047Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- University of Illinois, Chicago
- Elmhurst Memorial Hospital, Elmhurst
- Edward Hospital/Cancer Center, Naperville
- e altri 3
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 14 lug 2026 · NCT06592924Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
- Northwestern University, Chicago
In reclutamentoFase 2
Età 18 e oltre · Uomini · Aggiornato il 14 lug 2026 · NCT05691465Study of ORIC-944 in Patients With Metastatic Prostate Cancer
- Illinois Cancer Specialists, Arlington Heights
- Comprehensive Urologic Care, Lake Barrington
In reclutamentoFase 1
Età 18 e oltre · Uomini · Aggiornato il 9 lug 2026 · NCT05413421CARE Tool Study Aim 3
- Alton Memorial Hospital, Alton
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 lug 2026 · NCT07296887rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
- Northwestern University, Chicago
In reclutamentoFase 1 inizialeVolontari sani benvenuti
Età 18 e oltre · Uomini · Aggiornato il 2 lug 2026 · NCT05852041Integrated Cancer Repository for Cancer Research
- Rush-Copley Cancer Care Center, Aurora
- Rush-Copley Healthcare Center, Yorkville
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 19 a 110 · Tutti i sessi · Aggiornato il 29 giu 2026 · NCT02012699Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- Northwestern Medicine Chicago Proton Center, Warrenville
In reclutamento
Età 18 e oltre · Uomini · Aggiornato il 17 giu 2026 · NCT00969111Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
- UChicago Medicine Comprehensive Cancer Center, Chicago
In reclutamentoFase 2
Età 18 e oltre · Uomini · Aggiornato il 16 giu 2026 · NCT05790213International Registry for Men With Advanced Prostate Cancer (IRONMAN)
- University of Illinois at Chicago, Chicago
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
- University of Chicago, Chicago
- e altri 3
In reclutamentoStudio osservazionale
Età 21 e oltre · Uomini · Aggiornato il 22 mag 2026 · NCT03151629Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.